Leukocyte-poor PRP extraction device

Abstract

The utility model discloses a leukocyte-poor PRP (platelet rich protein) extraction device. The centrifugal tube comprises a centrifugal tube body and a tube plug which are buckled with each other, the centrifugal tube body sequentially comprises a first containing cavity, a second containing cavity and a third containing cavity from top to bottom, the first containing cavity, the second containing cavity and the third containing cavity are communicated in sequence, and the inner diameter of the second containing cavity is smaller than that of the third containing cavity; the piston is embedded in the third accommodating cavity in a manner of moving up and down; the device further comprises a separation assembly arranged in the third containing cavity in a penetrating mode, and the separation assembly moves in the length direction of the second containing cavity so as to communicate or close the second containing cavity and the third containing cavity. The pipe plug extends towards the first containing cavity and is provided with a protrusion. The scheme provides a leukocyte-poor platelet plasma (P-LR PRP) extraction device which is efficient and simple and convenient to operate. According to the device, high-concentration platelets can be effectively separated and extracted in simple operation, meanwhile, the content of white blood cells is remarkably reduced, the operation steps are simplified, and the pollution risk is reduced.

Description

Technical Field

[0001] The utility model relates to the technical field of medical devices, in particular to a leukocyte-poor PRP extraction device. Background Art

[0002] Platelet-rich plasma (PRP) has been widely used in the medical field, especially in regenerative medicine, trauma treatment, and cosmetic medicine. PRP helps accelerate tissue repair and regeneration through its high concentration of platelets and growth factors. However, the traditional PRP extraction process usually also extracts a high number of white blood cells, which may cause an inflammatory response and be detrimental to the treatment effect. For example:

[0003] Arthritis: LP-PRP helps reduce inflammation and pain and promotes cartilage repair. Suitable for knee arthritis, hip arthritis, etc.

[0004] Tendinopathy: Used to treat chronic tendinopathy such as tennis elbow and Achilles tendonitis because its low white blood cell count reduces inflammatory response.

[0005] Cosmetic Surgery: Used in skin regeneration and anti-aging treatments, such as facial skin rejuvenation, where its low-inflammatory properties help reduce swelling and pain.

[0006] Soft tissue injuries: including muscle tears, ligament injuries, etc. LP-PRP helps accelerate the healing process and reduce inflammatory response.

[0007] Therefore, the demand for leukocyte-poor platelet plasma (LR-PRP) is increasing because it can significantly reduce the content of white blood cells while providing high concentrations of platelets, thereby reducing the inflammatory response and improving the therapeutic effect.

[0008] Most PRP extraction devices currently on the market only perform standard PRP extraction and are unable to effectively remove white blood cells. Existing techniques rely primarily on multiple centrifugation and manual manipulation to separate white blood cells, a complex and time-consuming process that can easily introduce contamination, reducing extraction efficiency and PRP purity. Furthermore, existing devices often handle blood samples in an inappropriately gentle manner, potentially reducing platelet activity and compromising the ultimate therapeutic effect. Utility Model Content

[0009] In view of the problems existing in the above-mentioned prior art, the present invention provides a leukocyte-poor PRP extraction device, which can effectively solve the problems existing in the above-mentioned prior art.

[0010] The technical solution of the utility model is:

[0011] According to one aspect of the present invention, the invention comprises: a centrifuge tube and a tube plug that are interlocked, wherein the centrifuge tube comprises, from top to bottom, a first accommodating chamber, a second accommodating chamber, and a third accommodating chamber that are sequentially connected, and the inner diameter of the second accommodating chamber is smaller than the inner diameter of the third accommodating chamber;

[0012] It also includes a piston, which is embedded in the third accommodating chamber so as to be movable up and down;

[0013] The device further includes a separation component disposed in the third accommodating cavity, wherein the separation component moves along the length direction of the second accommodating cavity to connect or close the second accommodating cavity and the third accommodating cavity;

[0014] The pipe plug is provided with a protrusion extending toward the first accommodating cavity.

[0015] Furthermore, the volume of the collected blood sample is defined as L ml, and the minimum volume of the third accommodating chamber when it reaches the top limit position is (0.30-0.35)*L.

[0016] Furthermore, the volume of the second accommodating cavity is (0.2-0.3)*L.

[0017] Furthermore, the inner diameter of the second accommodating cavity is 1 to 1.8 cm.

[0018] Furthermore, it also includes a base, one end of the piston is fixedly connected to the base, and the base is covered with a threaded connection cover on the opening of the third accommodating chamber.

[0019] Furthermore, a connecting rod is provided at one end of the base extending toward the third accommodating cavity, the connecting rod is provided with a limiting flange, the piston is correspondingly provided with a limiting groove, and the limiting flange is engaged with the limiting groove.

[0020] Furthermore, the separation assembly includes a plug, a screw and a knob, the screw is provided through the base and the third accommodating cavity, and the screw is threadedly connected to the base;

[0021] One end of the screw is fixedly provided with a plug for blocking the second accommodating cavity, and the other end is fixedly provided with a knob;

[0022] Driven by the screw, the plug can move along the length direction of the second accommodating cavity to connect or close the second accommodating cavity and the third accommodating cavity.

[0023] Furthermore, the height of the protrusion is 3 to 6 mm.

[0024] Furthermore, it also includes a support frame, which is fixedly sleeved on the outside of the pipe plug and is threadedly connected to the first accommodating cavity.

[0025] Furthermore, the pipe plug is made of silicone.

[0026] By adopting the above technical solution, the present invention has the following beneficial effects compared with the prior art:

[0027] This solution provides an efficient and easy-to-use device for extracting leukocyte-poor platelet plasma (P-LR PRP). This device can effectively separate and extract high-concentration platelets in a simple operation, while significantly reducing the white blood cell count. This simplifies the operation steps, reduces contamination risks, and improves extraction efficiency and platelet activity, thereby better meeting clinical needs. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0029] Figure 1 This is a schematic diagram of the vertical cross-sectional structure of the extraction device in the present invention;

[0030] Figure 2 This is a schematic cross-sectional view of the plug plugging the second accommodating cavity in the present invention;

[0031] Figure 3 This is a structural diagram of the injection device inserted into the first accommodating cavity when the extraction device is rotated 180° and the extraction device is reversed to vertical position in the present invention;

[0032] In the figure: centrifuge tube-1, first accommodating chamber-11, third accommodating chamber-12, second accommodating chamber-13, tube plug-2, inclined surface-21, protrusion-22, support frame-3, piston-4, limiting groove-41, base-5, connecting rod-51, limiting flange-52, separation component-6, plug-61, screw-62, knob-63, injection device-A. DETAILED DESCRIPTION

[0033] The present invention will be further described in detail below with reference to the accompanying drawings and examples. It should be noted that the following examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. Similarly, the following examples are merely partial embodiments of the present invention and are not intended to be exhaustive. All other embodiments derived by persons of ordinary skill in the art without inventive effort are intended to fall within the scope of protection of the present invention.

[0034] like Figures 1 to 3 As shown, this solution provides a leukocyte-poor PRP extraction device.

[0035] See Figure 1 and Figure 2 The extraction device comprises a centrifuge tube 1 and a tube plug 2 that interlock together. In this embodiment, it also includes a support frame 3, which is fixedly mounted on the outside of the tube plug 2 and threadedly connected to the first accommodating chamber. The tube plug 2 is made of silicone and facilitates insertion of the injection device A into the tube plug 2 for collecting platelets and plasma.

[0036] See Figure 1 and Figure 2 , further comprising a base 5 and a piston 4. The piston 4 is embedded in the third accommodating chamber 12 so as to be movable up and down. One end of the piston 4 is fixedly connected to the base 5. The base 5 is covered with a threaded connection cover at the opening of the third accommodating chamber 12. The initial state of the base 5 is to rotate toward the third accommodating chamber 12 to the extreme position. Specifically, the internal thread of the base 5 is matched with the external thread of the third accommodating chamber 12. Preferably, a connecting rod 51 is provided at one end of the base 5 extending toward the third accommodating chamber 12. The connecting rod 51 is provided with a limiting flange 52. The piston 4 is correspondingly provided with a limiting groove 41, and the limiting flange 52 is engaged with the limiting groove 41.

[0037] See Figure 1 and Figure 2 , the centrifuge tube 1 includes, from top to bottom, a first accommodating chamber 11, a second accommodating chamber 13, and a third accommodating chamber 12, which are connected in sequence. The inner diameter of the second accommodating chamber 13 is smaller than the inner diameter of the third accommodating chamber 12. The volume of the collected blood sample is defined as Lml, wherein L can be 5 to 100ml. In many embodiments, L is 10 to 30ml. In this embodiment, L is approximately 20ml. Since the red blood cell content in normal human whole blood is between 35% and 55%. The white blood cell content in normal human whole blood is between 0.5% and 1.5%. After the whole blood is centrifuged, obvious stratification will be formed according to the different densities of each component. Among them, the white blood cell layer is located between the plasma layer and the red blood cell layer, presenting a relatively thin white layered structure. Typically, to ensure that the boundary between the white blood cell layer and the plasma is located within the second accommodating chamber 13 during the subsequent separation process, the third accommodating chamber 12 preferably has a minimum volume of 0.30 to 0.35 L at its top limit, more preferably 0.33 to 0.34 L at its top limit. In this embodiment, the minimum volume of the third accommodating chamber 12 at its top limit is approximately 6.8 ml. The maximum volume of the third accommodating chamber 12 at its bottom limit is not limited, but preferably can be approximately 0.5 L. In this embodiment, the maximum volume of the third accommodating chamber 12 at its bottom limit is approximately 10 ml.

[0038] The volume of the second accommodating chamber 13 is preferably 0.2 to 0.3 L. This has the advantage that when approximately 35% of the red blood cells fill the third accommodating chamber 12 at the top limit during the first centrifugation, the remaining red blood cells and white blood cell layer will be located in the second accommodating chamber 13, so that the boundary between white blood cells and plasma is also located in the second accommodating chamber 13, facilitating the subsequent separation of the red blood cell layer, the white blood cell layer, and the plasma. In this embodiment, the volume of the second accommodating chamber 13 is preferably 4 to 6 ml, and preferably, the volume of the second accommodating chamber 13 is preferably 5 ml.

[0039] In this embodiment, further, in order to make the boundary between white blood cells and plasma more obvious, under the premise that the volume of the second accommodating chamber 13 remains unchanged, the inner diameter of the second accommodating chamber 13 can be further reduced to increase the height of the second accommodating chamber 13. However, as the inner diameter decreases, the stratification of white blood cells and plasma will not be complete (as the inner diameter decreases, the centrifugal force also decreases, F = mω2r, where F represents centrifugal force, m represents mass, ω represents angular velocity, and r represents radius). Experiments have shown that when the inner diameter of the second accommodating chamber 13 is less than 1 cm, it is difficult to effectively separate white blood cells and plasma when the centrifugal force of the first centrifugation is 400g (g is the acceleration of gravity). Take the volume of the second accommodating chamber 13 as an example of 5ml (V = π*R 2 *h, V represents volume, R represents radius, and h represents height). Preferably, the inner diameter of the second accommodating chamber 13 is 1 cm to 1.8 cm, which corresponds to a height of the second accommodating chamber 13 of 6.37 to 1.97 cm; more preferably, the inner diameter of the second accommodating chamber 13 is 1.2 cm to 1.6 cm, which corresponds to a height of the second accommodating chamber 13 of 4.42 to 2.49 cm.

[0040] See Figures 1 to 3 , also includes a separation component 6 passed through the third accommodating chamber 12, the separation component 6 moves along the length direction of the second accommodating chamber 13 to connect or close the second accommodating chamber 13 and the third accommodating chamber 12; preferably, the separation component 6 includes a plug 61, a screw 62 and a knob 63, the screw 62 passes through the base 5 and the third accommodating chamber 12, and the screw 62 is threadedly connected to the base 5; the plug 61 can be driven by the screw 62 to move along the length direction of the second accommodating chamber 13 to connect or close the second accommodating chamber 13 and the third accommodating chamber 12; one end of the screw 62 is fixed with a plug 61 for blocking the second accommodating chamber 13, and the other end is fixed with a knob 63.

[0041] See Figure 1 and Figure 2One end of the tube plug 2 is provided with an annular inclined surface 21 extending toward the inner circumference of the first accommodating chamber 11. Therefore, when the extraction device is vertically reversed, the space between the junction of the first accommodating chamber 11 and the tube plug 2 and the upper end surface of the first accommodating chamber 11 is wide at the top and narrow at the bottom, facilitating observation of the platelet and plasma collection process.

[0042] See Figures 1 to 3 , the tube plug 2 is provided with a protrusion 22 extending toward the first accommodating chamber 11. The height of the protrusion 22 is 3 to 6 mm, and preferably, the height of the protrusion 22 is 4 mm. To ensure that the white blood cells after the second centrifugation can be concentrated around the protrusion 22, the injection device A is inserted into the top of the protrusion 22, and the white blood cells can be avoided when collecting platelets and plasma. The raised surface of the protrusion 22 is arc-shaped. When the second centrifugation is performed, the extraction device is turned 180°. After centrifugation, the white blood cells will be concentrated around the protrusion 22. At this time, the injection device A is inserted into the arc-shaped top of the protrusion 22 to collect the platelets and plasma.

[0043] The extraction method includes the following steps:

[0044] S1, place the extraction device in a forward vertical position, rotate the base 5 toward the third accommodating chamber 12 to the top limit position, and then move the plug 61 away from the second accommodating chamber 13 to connect the first accommodating chamber 11, the second accommodating chamber 13, and the third accommodating chamber 12;

[0045] S2, injecting the collected blood sample into the centrifuge tube 1; the step of injecting the collected blood sample into the centrifuge tube 1 specifically includes: inserting the injection device A from the top of the tube plug 2 and injecting the collected blood sample into the centrifuge tube 1.

[0046] S3, starting the centrifuge, controlling the centrifugal force and time of the centrifuge to perform the first centrifugation, so that the blood sample is separated from the bottom to the top into a red blood cell layer, a white blood cell layer, and a plasma layer; the step of controlling the centrifugal force and time of the centrifuge to perform the first centrifugation, so that the blood sample is separated from the bottom to the top into a red blood cell layer, a white blood cell layer, and a plasma layer specifically includes: controlling the centrifugal force of the centrifuge to 380-420g and the centrifugation time to 3-10 minutes for the first centrifugation, so that the blood sample is separated from the bottom to the top into a red blood cell layer, a white blood cell layer, and a plasma layer. Preferably, the centrifugal force of the centrifuge is controlled to 400g and the centrifugation time is controlled to 5 minutes;

[0047] When the boundary line between the white blood cell layer and the plasma layer is located in the third accommodating chamber 12, a preliminary blood problem is determined and the procedure ends. When the boundary line between the red blood cell layer and the white blood cell layer is located in the third accommodating chamber 12, it means that the red blood cell and white blood cell content of the whole blood is between 35% and 57%.

[0048] When the boundary line between the white blood cell layer and the plasma layer is located in the first accommodating chamber 11, a blood problem is preliminarily determined and the procedure ends. When the boundary line between the red blood cell layer and the white blood cell layer is located in the first accommodating chamber 11, it means that the content of red blood cells and white blood cells in the whole blood exceeds 57%.

[0049] S4, slowly rotate the base 5 to drive the piston 4 downward, so that the red blood cell layer and some white blood cells in the second accommodating chamber 13 slowly flow into the third accommodating chamber 12, so that the boundary between the white blood cell layer and the plasma layer is located at the bottom of the second accommodating chamber 13;

[0050] S5, slowly turn the knob 63 to make the screw 62 drive the plug 61 to move toward the second accommodating chamber 13, so that the plug 61 is blocked in the second accommodating chamber 13, thereby separating the white blood cell layer from the plasma layer; when the knob 63 is slowly turned to make the screw 62 drive the plug 61 to move toward the second accommodating chamber 13, when the boundary line between the white blood cell layer and the plasma layer rises significantly, the base 5 is slowly rotated to drive the piston 4 to move downward, so that the boundary line between the white blood cell layer and the plasma layer is always located at the bottom of the second accommodating chamber 13.

[0051] S6, turning the extraction device 180°, starting the centrifuge, and controlling the centrifugal force and time of the centrifuge to perform a second centrifugation, so that the white blood cells are concentrated at the bottom end around the protrusion 22, and the white blood cell-poor PRP is deposited on the white blood cell layer; turning the extraction device 180°, starting the centrifuge, and controlling the centrifugal force and time of the centrifuge to perform a second centrifugation, so that the platelets and some white blood cells are concentrated in the bottom layer, specifically includes: controlling the centrifugal force of the centrifuge to 950-1050g and the centrifugation time to 5-15 minutes for the second centrifugation, so that the platelets and some white blood cells are concentrated in the bottom layer. Preferably, the centrifugal force of the centrifuge is controlled to 1000g and the centrifugation time is controlled to 10 minutes.

[0052] S7, the injection device A is inserted from the bottom of the tube plug 2 into the protrusion 22 and then passed through the protrusion 22, thereby bypassing the white blood cells around the protrusion 22 and collecting the white blood cell-poor PRP. Specifically, the injection device A is inserted into the top of the protrusion 22 to collect platelets and plasma.

[0053] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments can still be modified, or some of the technical features thereof can be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the various embodiments of the present invention.

Claims

1. A leukocyte-poor PRP extraction device, comprising: A centrifuge tube (1) and a tube plug (2) that are interlocked, characterized in that the centrifuge tube (1) comprises, from top to bottom, a first accommodating chamber (11), a second accommodating chamber (13), and a third accommodating chamber (12) that are sequentially connected, and the inner diameter of the second accommodating chamber (13) is smaller than the inner diameter of the third accommodating chamber (12); It also includes a piston (4), which is embedded in the third accommodating chamber (12) so as to be movable up and down; It also includes a separation component (6) that is arranged in the third accommodating chamber (12), and the separation component (6) moves along the length direction of the second accommodating chamber (13) to connect or close the second accommodating chamber (13) and the third accommodating chamber (12); The pipe plug (2) is provided with a protrusion (22) extending toward the first accommodating cavity (11).

2. The leukocyte-poor PRP extraction device according to claim 1, characterized in that: The volume of the collected blood sample is defined as Lml, and the minimum volume of the third accommodating chamber (12) when it reaches the top limit position is (0.30-0.35)*L.

3. The leukocyte-poor PRP extraction device according to claim 2, characterized in that: The volume of the second accommodating cavity (13) is (0.2-0.3)*L.

4. The leukocyte-poor PRP extraction device according to claim 1, characterized in that: The inner diameter of the second accommodating cavity (13) is 1 to 1.8 cm.

5. The leukocyte-poor PRP extraction device according to claim 1, characterized in that: It also includes a base (5), one end of the piston (4) is fixedly connected to the base (5), and the base (5) is covered with a threaded connection cover at the opening of the third accommodating chamber (12).

6. The leukocyte-poor PRP extraction device according to claim 5, characterized in that: A connecting rod (51) is provided at one end of the base (5) extending toward the third accommodating chamber (12), the connecting rod (51) is provided with a limiting flange (52), the piston (4) is correspondingly provided with a limiting groove (41), and the limiting flange (52) is engaged with the limiting groove (41).

7. The leukocyte-poor PRP extraction device according to claim 1, characterized in that: The separation assembly (6) comprises a plug (61), a screw (62) and a knob (63), wherein the screw (62) is provided through the base (5) and the third accommodating cavity (12), and the screw (62) is threadedly connected to the base (5); One end of the screw rod (62) is fixedly provided with a plug (61) for blocking the second accommodating cavity (13), and the other end is fixedly provided with a knob (63); Driven by the screw rod (62), the plug (61) can move along the length direction of the second accommodating chamber (13) to connect or close the second accommodating chamber (13) and the third accommodating chamber (12).

8. The leukocyte-poor PRP extraction device according to claim 1, characterized in that: The height of the protrusion (22) is 3 to 6 mm.

9. The leukocyte-poor PRP extraction device according to claim 1, characterized in that: It also includes a support frame (3), which is fixedly sleeved on the outside of the pipe plug (2), and the support frame (3) is threadedly connected to the first accommodating cavity (11).

10. The leukocyte-poor PRP extraction device according to claim 9, characterized in that: The pipe plug (2) is made of silicone material.

Images